Company intelligence / Profile preview

iHealthScreen

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

iHealthScreen’s AI-driven retinal image analysis software is commercially deployed in the US and Bangladesh to screen and predict risk for diabetic retinopathy, AMD, stroke, CVD, and Alzheimer’s; clinical partnerships include validations at Mount Sinai, rollout with the Bangladesh Diabetes Society, and international service expansion. Their system has submitted for 510(k) clearance for AI-enabled AMD detection, with $2.5M NIH grant and $6.5M private/NIH investments supporting scaled deployment[1][2][4][5].

Therapeutic areas: NeurologyOphthalmologyCardiovascular
Modalities: DeviceArtificial intelligence software
Industry: Digital Health Medical Devices

Partnerships

Mount Sinai Hospital, USABangladesh Diabetes SocietyVarious community clinics (New York metropolitan area)

Beyond the preview

Go deeper on iHealthScreen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iHealthScreen.

Explore the full profile